证券代码：603127 证券简称：昭衍新药 公告编号：2024-054 北京昭衍新药研究中心股份有限公司 关于以集中竞价交易方式回购公司 A 股股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/3/29 | | --- | --- | | 回购方案实施期限 | 待董事会审议通过后 12 个月 | | 预计回购金额 | 万元 5,000 万元~10,000 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 210.31 万股 | | 累计已回购股数占总股本比例 | 0.2806% | | 累计已回购金额 | 3,319.60 万元 | | 实际回购价格区间 | 13.20 元/股~18.15 元/股 | 一、 回购股份的基本情况 北京昭衍新药研究中心股份有限公司（以下简称"公司"）于 2024 年 3 月 28 日召开第四届董事会第七次会议，审议通过了《昭 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2024年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京昭衍新藥研究中心股份有限公司 呈交日期: 2024年12月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06127 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 118,995,206 | RMB | | 1 | RMB | | 118,995,206 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 118,995,206 | RMB | | 1 | RMB | | 118,995,206 | | 2. 股份分 ...

证券代码：603127 证券简称：昭衍新药 公告编号：2024-053 北京昭衍新药研究中心股份有限公司 关于召开 2024 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2024 年 11 月 27 日（星期三）至 12 月 03 日（星期二）16:00 前 登 录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 jiafengsong@joinn-lab.com 进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 北京昭衍新药研究中心股份有限公司（以下简称"公司"）已于 2024 年 10 月 31 日发布公司 2024 年第三季度报告，为便于广大投资者更全面深入地了解公司 2024 年第三季度经营成果、财务状况，公司计划于 2024 年 12 月 04 日下午 16:00-17:00 举行 2024 年第三季度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络 ...

Investment Rating - Maintains an "Overweight" rating with a target price of 19.60 RMB [2] - The current price is 16.96 RMB, indicating potential upside [2] Core Views - Short-term pressure on gross margin, but order backlog supports growth [3] - Capacity expansion and internationalization are progressing steadily [3] - Revenue for 2024 Q1-Q3 was 1.335 billion RMB, down 15.87% YoY [3] - Net profit attributable to shareholders was -70 million RMB, with a significant loss from changes in fair value of biological assets [3] - Q3 revenue was 486 million RMB, down 15.51% YoY, with net profit of 99 million RMB, down 58.04% YoY [3] - EPS forecasts for 2024-2026 revised to 0.08/0.52/0.68 RMB from 0.65/0.76/0.88 RMB [3] - Gross margin for Q1-Q3 2024 was 27.48%, down 16.29 pct YoY, with Q3 gross margin at 22.43%, down 20.36 pct YoY [3] - Order backlog as of H1 2024 was 2.9 billion RMB, with new orders of 900 million RMB [3] Financial Summary - Revenue for 2024E is projected at 2.001 billion RMB, down 15.8% YoY [4] - Net profit attributable to shareholders for 2024E is expected to be 56 million RMB, down 85.8% YoY [4] - EPS for 2024E is forecasted at 0.08 RMB, with ROE at 0.7% [4] - Revenue for 2025E and 2026E is projected to grow by 15.2% and 14.2% respectively [4] - Net profit for 2025E and 2026E is expected to be 392 million RMB and 510 million RMB respectively [4] Capacity and Internationalization - Suzhou Zhaoyan Phase II facility (20,000 m²) is expected to be operational by early 2025 [3] - Suzhou's 22,000 m² supporting facility is expected to be completed by the end of 2024 [3] - Guangzhou safety evaluation base construction is progressing [3] - Overseas subsidiary Biomere secured new orders of approximately 140 million RMB in H1 2024 [3] - International revenue in 2023 was 579 million RMB, up 51.20% YoY [3] Market Data - 52-week stock price range is 12.46-28.58 RMB [5] - Total market capitalization is 12.711 billion RMB [5] - Total shares outstanding are 749 million, with 630 million A-shares [5] Balance Sheet Highlights - Shareholders' equity is 8.002 billion RMB [6] - Net asset per share is 10.68 RMB [6] - Price-to-book ratio is 1.6 [6] - Net debt ratio is -39.84% [6] Peer Comparison - Comparable companies include Pharmaron (300759 SZ) and WuXi AppTec (603259 SH) [10] - Average PE ratio for peers is 37.63x for 2024E and 22.62x for 2026E [10] Catalysts - Rapid release of new capacity [3] - Expansion of new businesses exceeding expectations [3] - Growth in order backlog [3]

证券代码：603127 证券简称：昭衍新药 公告编号：2024-052 北京昭衍新药研究中心股份有限公司 关于以集中竞价交易方式回购公司 A 股股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/3/29 | | --- | --- | | 回购方案实施期限 | 待董事会审议通过后 12 个月 | | 预计回购金额 | 万元 5,000 万元~10,000 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 210.31 万股 | | 累计已回购股数占总股本比例 | 0.2806% | | 累计已回购金额 | 3,319.60 万元 | | 实际回购价格区间 | 13.20 元/股~18.15 元/股 | 一、 回购股份的基本情况 经公司 2023 年年度权益分派除息后，回购股份价格上限由不超过人民币 28.10 元/股（含）调整为不超过人民币 27.94 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 第 1 頁 共 11 頁 v 1.1.0 截至月份: 2024年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京昭衍新藥研究中心股份有限公司 呈交日期: 2024年11月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06127 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 118,995,206 | RMB | | 1 RMB | | 118,995,206 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 118,995,206 | RMB | | 1 RMB | | 118,995,206 | | 2. ...

Financial Performance - Revenue for Q3 2024 was RMB 485,799,506.29, a decrease of 15.51% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2024 was RMB 99,435,565.54, down 58.04% year-on-year[2] - Net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2024 was RMB 84,926,745.33, a decline of 63.74% compared to the previous year[2] - Year-to-date net profit attributable to shareholders was RMB -70,307,075.11, a decrease of 121.46% compared to the same period last year[2] - Year-to-date revenue was RMB 1,335,156,050.40, down 15.87% year-on-year[2] - Basic earnings per share for Q3 2024 was RMB 0.13, a decrease of 59.38% compared to the same period last year[3] - The net profit for Q3 2024 was -74,244,009.94 RMB, a significant decrease compared to the net profit of 326,197,002.65 RMB in Q3 2023, representing a decline of approximately 122.7%[22] - Operating profit for Q3 2024 was -69,661,013.72 RMB, compared to an operating profit of 392,084,940.00 RMB in the same period last year, indicating a substantial drop[22] - Total operating revenue for the first three quarters of 2024 was CNY 1,335,156,050.40, a decrease of 15.8% compared to CNY 1,587,079,779.38 in the same period of 2023[20] - The total comprehensive income for Q3 2024 was -79,103,195.69 RMB, compared to 336,381,200.67 RMB in Q3 2023, indicating a decline of approximately 123.5%[23] Assets and Liabilities - Total assets at the end of the reporting period were RMB 9,525,184,807.98, a decrease of 5.01% from the end of the previous year[3] - Total assets amounted to CNY 9,525,184,807.98, down from CNY 10,027,159,630.47, a decrease of 5.0%[19] - Total liabilities decreased to CNY 1,534,350,209.75 from CNY 1,746,119,215.39, a reduction of 12.1%[19] - The company's total equity decreased to CNY 7,990,834,598.23 from CNY 8,281,040,415.08, a decline of 3.5%[19] - Inventory decreased to CNY 1,631,793,427.45 from CNY 1,863,081,944.56, a decrease of 12.4%[18] Cash Flow - The net cash flow from operating activities year-to-date was RMB 192,325,709.34, down 57.11% year-on-year[2] - The cash flow from operating activities for the first three quarters of 2024 was 192,325,709.34 RMB, a decrease from 448,440,218.42 RMB in the same period of 2023, showing a decline of approximately 57.1%[24] - The total cash inflow from investment activities for the first three quarters of 2024 was 2,508,098,115.21 RMB, a significant increase from 528,639,464.14 RMB in the same period of 2023[24] - The net cash flow from investing activities was -950,050,766.71, compared to -137,147,755.87 in the previous period, indicating a significant increase in cash outflow for investments[25] - The total cash outflow from financing activities was 248,828,091.97, down from 333,289,197.75 in the previous period, reflecting a reduction in financing costs[25] - The net increase in cash and cash equivalents was -1,013,522,516.10, compared to -8,194,783.60 in the previous period, showing a substantial decline in liquidity[25] - The ending balance of cash and cash equivalents was 1,840,124,511.87, down from 2,891,274,796.93 in the previous period, indicating a decrease in available cash[25] Shareholder Information - The total number of common shareholders at the end of the reporting period was 72,246, with no preferred shareholders having voting rights[9] - The largest shareholder, Feng Yuxia, holds 167,160,633 shares, representing 22.30% of the total shares[10] - The second largest shareholder, HKSCC Nominees Limited, holds 118,974,786 shares, accounting for 15.87%[10] - The company has not reported any changes in the top 10 shareholders due to margin trading or stock lending activities during the reporting period[14] - The top 10 shareholders include several institutional investors, with the largest being a medical index fund[12] Business Operations - The contribution of laboratory service business to net profit year-to-date was RMB -1,705,100, a decline of 100.55% compared to the previous year[4] - The fair value change of biological assets resulted in a net loss of RMB 17,698,420.00 year-to-date[4] - The total new signed orders for the first three quarters amounted to approximately RMB 1.4 billion, with the total outstanding orders at approximately RMB 2.65 billion as of the report date[15] - The outstanding orders execution is influenced by various factors, and investors are advised to pay attention to investment risks[15] - The company has not disclosed any new product developments or market expansion strategies in the current report[11] - The company is focusing on expanding its market presence and enhancing its product development capabilities, although specific new products or technologies were not detailed in the report[20] Research and Development - Research and development expenses for Q3 2024 were 71,085,657.06 RMB, down from 77,639,680.27 RMB in Q3 2023, reflecting a decrease of about 8.1%[22] Accounting and Standards - The company’s financial statements are unaudited as of September 30, 2024[16] - The company has adopted new accounting standards starting in 2024, which may impact future financial reporting[26]

北京昭衍新药研究中心股份有限公司章程 北京昭衍新药研究中心股份有限公司 章程 二零二四年十月 1 | | 北京昭衍新药研究中心股份有限公司章程 3 | | --- | --- | | 第一章 | 总则 3 | | 第二章 | 经营宗旨和范围 4 | | 第三章 | 股份 5 | | | 第一节 股份发行 5 | | | 第二节 股份增减和回购 7 | | | 第三节 股份转让 10 | | | 第四节 购买公司股份的财务资助 12 | | | 第五节 股票和股东名册 13 | | 第四章 | 股东和股东大会 17 | | | 第一节 股东 17 | | | 第二节 股东大会的一般规定 22 | | | 第三节 股东大会的召集 25 | | | 第四节 股东大会的提案与通知 26 | | | 第五节 股东大会的召开 29 | | | 第六节 股东大会的表决和决议 33 | | | 第七节 类别股东表决的特别程序 38 | | 第五章 | 董事会 41 | | | 第一节 董事 41 | | | 第二节 董事会 45 | | | 第三节 董事会专门委员会 53 | | 第六章 | 总经理及其他高级管理人员 54 ...

证券代码：603127 证券简称：昭衍新药 公告编号：2024-051 北京昭衍新药研究中心股份有限公司 关于董事辞任及补选非独立董事的公告 本公司董事会及全体董事保证公告内容不存在虚假记载、误导性陈述或 者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 北京昭衍新药研究中心股份有限公司（下称"公司"或"昭衍新药"）董事会于 近日收到姚大林先生辞去董事、副总经理职务的书面辞呈，姚大林先生因个人及 工作原因申请辞去公司董事、副总经理职务。姚大林先生辞去上述职务后，将继 续在公司其他子公司任职。 截至本公告披露日，姚大林先生持有公司 A 股股份 76,458 股。 根据《公司法》《公司章程》等规定，经公司股东提名、董事会提名委员会 资格审核，公司于 2024 年 10 月 30 日召开第四届董事会第十次会议，审议通过 了《关于补选公司第四届董事会非独立董事的议案》，同意补选罗樨女士（简历 附后）为公司第四届董事会非独立董事候选人，任期自股东大会审议通过之日起 至第四届董事会届满之日止。该事项尚需提交公司股东大会审议。 特此公告。 北京昭衍新药研究中心股份有限公司董事会 2024 年 10 月 30 ...

证券代码：603127 证券简称：昭衍新药 公告编号：2024-048 北京昭衍新药研究中心股份有限公司 第四届董事会第十次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 北京昭衍新药研究中心股份有限公司（以下简称"公司"或"昭衍新药"）第四 届董事会第十次会议于 2024 年 10 月 16 日以书面送达、电子邮件等方式发出会 议通知，并于 2024 年 10 月 30 日在公司会议室以现场会议和电话会议的形式召 开。本次会议应参加董事 9 人，实际参加董事 9 人，会议由董事长冯宇霞女士主 持；公司全部监事和部分高级管理人员列席会议。会议的召集和召开及表决符合 《中华人民共和国公司法》和《北京昭衍新药研究中心股份有限公司章程》（以 下简称"《公司章程》"）的规定，会议程序合法、有效。 本次会议经与会董事认真审议，以举手表决方式作出了如下决议： 1.审议通过《关于公司 2024 年第三季度报告的议案》 根据《公司法》《公司章程》等规定，经公司股东提名、董事会提名委员会 资格审核，董事会同意补选罗樨女士为公司第四 ...